Akero Therapeutics Inc’s recent filing unveils that its Chief Scientific Officer Rolph Timothy unloaded Company’s shares for reported $1.38 million on Jun 06 ’25. In the deal valued at $55.04 per share,25,000 shares were sold. As a result of this transaction, Rolph Timothy now holds 169,721 shares worth roughly $9.29 million.
Then, Rolph Timothy sold 12,500 shares, generating $668,634 in total proceeds. Upon selling the shares at $53.49, the Chief Scientific Officer now owns 169,721 shares.
Before that, Lamy Patrick sold 4,000 shares. Akero Therapeutics Inc shares valued at $201,258 were divested by the Senior VP, Commercial Strategy at a price of $50.31 per share. As a result of the transaction, Lamy Patrick now holds 33,492 shares, worth roughly $1.83 million.
BofA Securities upgraded its Akero Therapeutics Inc [AKRO] rating to a Buy from a a Neutral in a research note published on January 30, 2025; the price target was increased to $63 from $35. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who remained covering the stock and in late January has reiterated a ‘”a Buy”‘ rating for it. Citigroup began covering AKRO with “Buy” recommendation on November 18, 2024.
Price Performance Review of AKRO
On Monday, Akero Therapeutics Inc [NASDAQ:AKRO] saw its stock jump 0.79% to $54.71. Over the last five days, the stock has gained 7.85%. Akero Therapeutics Inc shares have risen nearly 96.66% since the year began. Nevertheless, the stocks have risen 163.16% over the past one year. While a 52-week high of $58.40 was reached on 01/27/25, a 52-week low of $20.64 was recorded on 01/14/25. SMA at 50 days reached $42.70, while 200 days put it at $36.45.
Levels Of Support And Resistance For AKRO Stock
The 24-hour chart illustrates a support level at 52.30, which if violated will result in even more drops to 49.90. On the upside, there is a resistance level at 57.09. A further resistance level may holdings at 59.48. The Relative Strength Index (RSI) on the 14-day chart is 71.10, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 4.42, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 12.30%. Stochastics %K at 92.46% indicates the stock is a selling.
How much short interest is there in Akero Therapeutics Inc?
A steep rise in short interest was recorded in Akero Therapeutics Inc stocks on 2025-05-15, dropping by 11766.0 shares to a total of 6.3 million shares. Yahoo Finance data shows the prior-month short interest on 2025-04-15 was 6.31 million shares. There was a decline of -0.19%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on September 19, 2023 when Cantor Fitzgerald began covering the stock and recommended ‘”an Overweight”‘ rating along with a $69 price target.
